Dissecting the Heterogeneity of Treatment Response in First-Episode Schizophrenia
Open Access
- 2 September 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 41 (6) , 1224-1226
Abstract
The Mental Health Centers for Intervention Development and Applied Research (CIDAR) program prioritized research to provide an evidence base for biomarker development. At the Zucker Hillside Hospital (ZHH), our CIDAR grant supported research on a comprehensive investigation of treatment response and outcome in first episode schizophrenia. Results provide evidence that baseline neuroimaging, neurocognitive, and genetic measures are significantly associated with clinical response to treatment, and that our currently available interventions can effectively treat aspects of psychotic illness, as well as potentially reduce comorbidity associated with illness. Future research may include combining modalities to more robustly predict response and identify treatment targets, as well as to further develop more effective intervention strategies for these devastating and disabling disorders.Keywords
This publication has 14 references indexed in Scilit:
- Baseline Striatal Functional Connectivity as a Predictor of Response to Antipsychotic Drug TreatmentAmerican Journal of Psychiatry, 2016
- Abnormal Resting State fMRI Activity Predicts Processing Speed Deficits in First-Episode PsychosisNeuropsychopharmacology, 2015
- Early-Course Unmedicated Schizophrenia Patients Exhibit Elevated Prefrontal Connectivity Associated with Longitudinal ChangeJournal of Neuroscience, 2015
- Antipsychotic Treatment and Functional Connectivity of the Striatum in First-Episode SchizophreniaJAMA Psychiatry, 2015
- Biological insights from 108 schizophrenia-associated genetic lociNature, 2014
- Association Between Common Variants Near the Melanocortin 4 Receptor Gene and Severe Antipsychotic Drug–Induced Weight GainArchives of General Psychiatry, 2012
- Cognitive Improvement After Treatment With Second-Generation Antipsychotic Medications in First-Episode SchizophreniaArchives of General Psychiatry, 2007
- Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE TrialArchives of General Psychiatry, 2007
- DRD2 Promoter Region Variation as a Predictor of Sustained Response to Antipsychotic Medication in First-Episode Schizophrenia PatientsAmerican Journal of Psychiatry, 2006
- A Summary of the FDA-NIMH-MATRICS Workshop on Clinical Trial Design for Neurocognitive Drugs for SchizophreniaSchizophrenia Bulletin, 2005